
Antibodiesinc/ASIC1/73-277/1 Ea
商品编号:
73-277
市场价:
¥0.00
美元价:
0.00
产品分类:
重组抗体
公司分类:
Recombinant_antibodies
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Fusion protein amino acids 460-526 (cytoplasmic C-terminus) of mouse ASIC1
(also known as Acid-sensing ion channel 1, Neuronal amiloride-sensitive cation channel 2, Brain sodium channel 2, BNaC2 and Accn2, accession number Q6NXK8)
Rat: 98% identity (66/67 amino acids identical)
Human: 97% identity (65/67 amino acids identical)
100% identity between ASIC1a and ASIC1b
<40% identity with ASIC4
(also known as Acid-sensing ion channel 1, Neuronal amiloride-sensitive cation channel 2, Brain sodium channel 2, BNaC2 and Accn2, accession number Q6NXK8)
Rat: 98% identity (66/67 amino acids identical)
Human: 97% identity (65/67 amino acids identical)
100% identity between ASIC1a and ASIC1b
<40% identity with ASIC4
Specifications:
Target |
![]() |
ASIC1 |
![]() |
||
Channel Target |
![]() |
Other Ion Channels |
![]() |
||
Applications |
![]() |
Immunoblot (IB) Immunocytochemistry (ICC) Immunohistochemistry (IHC) |
![]() |
||
Clone |
![]() |
N271/44 |
![]() |
||
IgG Isotype |
![]() |
IgG1 |
![]() |
||
Species Reactivity |
![]() |
Mouse (M) Rat (R) |
![]() |
||
Validation |
![]() |
Br-IB Br-IHC KO T |
![]() |
||
Type |
![]() |
TC Supernatant |
![]() |
||
Format |
![]() |
5 mL |
![]() |
||
Cross Reactivity |
![]() |
Does not cross-react with ASIC2 |
![]() |
||
Expected Banding Pattern |
![]() |
60 kDa |
![]() |
||
Host |
![]() |
Mouse (M) |
![]() |
||
Label |
![]() |
Unlabeled |
![]() |
||
Antibody Type |
![]() |
Monoclonal |
![]() |
||
Commercial Price |
![]() |
390 |
![]() |
||
Non-Profit Price |
![]() |
175 |
![]() |
||
Distributor Price |
![]() |
Per Contract(QUOTE) |
![]() |
||
ABID |
![]() |
RRID:AB_11000719 |
![]() |
品牌介绍
当抗体公司(Antibodies Incorporated)在1962年开业时,与抗体相关的研究才刚刚开始。创始人Jim Hillman拥有博士学位。从药理学明尼苏达大学,来到加州大学戴维斯分校在免疫化学完整的博士后工作,在工作期间,他学习了加州理工学院(加州理工学院)根据丹·坎贝尔,领域的先驱。吉姆带来了他的妻子,公司的共同创始人卡罗尔(Carol)和两个孩子,以及使用基于抗体的化学疗法寻找治疗癌症的能量和想法。具体地说,吉姆认为,如果他能够识别并分离出可能具有抗原性的肿瘤部位(一个焦点是淋巴肉瘤),则可能有可能进行有效的基于抗体的治疗。吉姆寻找这种治疗方法的梦想推动了他的工作多年。